Physician profile
Michael Rasmussen
NPI 1487056339
$1,129.99
in general payments reported to CMS, 2019-2025
21 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $237 · 2023: $219 · 2024: $293 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.13 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $179.44 | 2021-2024 | Xarelto |
| Amarin Pharma, INC. | $109.19 | 2021-2022 | |
| Lilly USA, LLC | $56.28 | 2021-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $53.20 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $42.46 | 2021-2024 | Airsupra, Breztri |
| Novo Nordisk INC | $41.69 | 2023-2025 | Rybelsus, Ozempic |
| Amgen INC. | $40.89 | 2024 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.74 | 2025 | Caplyta |
| Abbvie INC. | $34.42 | 2022-2025 | |
| Seqirus USA INC | $22.56 | 2025 | Fluad, Flucelvax |
| Sanofi Pasteur INC. | $22.41 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.94 | 2025 | Zoryve |
| Dexcom, INC. | $18.13 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $17.62 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $17.19 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $14.99 | 2023 | |
| Glaxosmithkline, LLC. | $13.38 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.08 | 2023 | |
| Athena Bioscience, LLC | $11.88 | 2023 | Nexiclon Xr |
| Supernus Pharmaceuticals, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rasmussen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.